The global cancer biomarkers market was valued at $10,944.08 million in 2019, and is projected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027.
Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are being used for diagnostics, prognostics, personalized medicines, and surrogate endpoints. The identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals.
The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.
The market is segmented on the basis of profiling technology, biomolecule, cancer type, application, and region. By profiling technology, the market is bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By biomolecule, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, the market is segmented as breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Based on application, the market is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Profiling Technology
- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics-based Tests
By Biomolecule
- Genetic Biomarkers
- Protein Biomarkers
- Glyco-biomarkers
By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
By Application
- Diagnostics
- Drug Discovery and Development
- Prognostics
- Risk Assessment
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Compnay
- Exact Sciences Corporation
- F.Hoffmann-La Roche Ltd.
- Merck KGaA
- PerkinElmer, Inc.
- Qiagen N.V.
- Siemens AG
- Thermo Fisher Scientific, Inc.
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Cancer Biomarkers Market, by Profiling Technology
Chapter 5: Cancer Biomarkers Market, by Biomolecule
Chapter 6: Cancer Biosensors Market, by Cancer Type
Chapter 7: Cancer Biomarker Market, by Application
Chapter 8: Cancer Biomarkers Market, by Region
Chapter 9: Company Profiles
Executive Summary
According to the report titled, 'Cancer Biomarkers Market By Profiling Technology, Biomolecule, Cancer Type, and Application: Opportunity Analysis and Industry Forecast, 2020 - 2027', the global cancer biomarkers market size is expected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027, in terms of value.The global cancer biomarkers market was valued at $10,944.08 million in 2019 and is expected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027. Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids that indicate an abnormal process or a disease.The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment.As biomarkers are used for diagnostics, prognostics, personalized medicines, and surrogate endpoints, identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals.
The global cancer biomarker market has witnessed an unprecedented growth in past few years. Rise in importance of biological and targeted drug therapies, technological developments, and surgein prevalence of various types of cancers contribute toward the cancer biomarker market growth. Moreover, cancer biomarkers are commonly used, as they are more reliable and accurate than other diagnostic techniques. The market is expected to grow at a significant pace during the forecast period.The market is estimated to gain momentum in developing regions of Asia-Pacific and Latin America. Factors such as rapid urbanization, increase in geriatric population and undiagnosed patients, surge in the adoption of remote patient monitoring devices, rise in disposable income, and surge inawareness about the benefits of cancer biomarkers are expected to boost the market growth in these regions.
By profiling technologies, the market is bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. Amongst these, omic technologies and imaging technologies segments collectively accounted for 79.5% of the total cancer biomarker market share in 2019, with the former constituting 54%share. The omic technologies segment is expected to exhibit a prominent growth rate in the future, owing to its efficiency in early diagnosis of cancer.However, immunoassay is anticipated to be the fastest growing segment and is estimated to garner $4,581.08 million by 2027, registering a CAGR of 16.40%.
On the basis of biomolecule, the cancer biomarker market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. Amongst these, genetic biomarkers are widely used in the market,as it is a better diagnostic and therapeutic technique as compared to protein and glyco-biomarkers. Thus, genetic biomarkers segment dominated the cancer biomarker market, governing 48.4% of the global cancer biomarker market value in 2019. It is estimated to garner $12,532.76 million by 2027, registering a CAGR of 11.2%. As glycan related molecules are more stable then proteins and nucleic acid, the popularity of glyco-biomarkers is on the rise. Thus, glyco-biomarker is the fastest growing segment and is estimated to garner $5,379.26 million by 2027, registering a CAGR of 12.5% during the forecast period.
On the basis of cancer type, the market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Amongst these, lung cancer is the major cancer type where biomarkers are used for detection. Owing to high tobacco consumption and smoking, lung cancer has increased at an alarming rate. Thus, is the fastest growing segment and is estimated to garner $2,714.03 million by 2027, registering a CAGR of 14.7%. However, high prevalence of breast cancer has dominated the market, and is estimated to garner $2,648.98 million by 2027, registering a CAGR of 16.7%.
The cancer biomarker market is segmented across five categories by application diagnostics, drug discovery and development, prognostics, risk assessment, and others. The prognostics segment dominated the market in 2019 and is estimated to garner $7,181.49 million by 2027, registering a CAGR of 11.2%. However, the diagnostics segment is estimated to be the fastest growing segment and is expected to garner $7,077.51 million by 2027 registering a CAGR of 12.0%.
North America and Europe are the most lucrative markets due to increase in prevalence of various cancer cases, growth in awareness toward cancer, higher cancer biomarker testing, well-established reimbursement policies, and high disposable income. The North America cancer biomarker market generated $3,988.02 million revenue in 2019, and is estimated to garner an approximate revenue of $8,733.26 million by 2027, at an estimated CAGR of 10.1%. The Asia-Pacific cancer biomarker market is estimated to account for the fastest growing segment globally. It is estimated to garner an approximate revenue of $7,519.19 million by 2027, registering an estimated CAGR of 15.1%. The steady market growth in this region is primarily attributed to the presence of large patient population, improving access to healthcare systems, and high risk of developing diseases due to rapid urbanization.
North America accounted for the majority of the global cancer biomarkers market share in 2019, and is anticipated remain dominant during the forecast period. This is attributed to the urge in use of cancer biomarkers and high incidence rate of cancer in the region. However, Asia-Pacific is anticipated to grow at the fastest rate during the forecast period, owing to the rise in incidence rate of cancer in countries such as China, Japan, and India andrise inawareness and affordability for advanced cancer treatments.
Key Findings of the Study
By profiling technologies,the omic technologies segment accounted for the highest market share of 54% in 2019,and is anticipated to grow at the fastest rate during the forecast period.
By region, North America was the major shareholder and accounted for the highest share of 36% in 2019.
Based on cancer type, thebreast cancersegment is expected to grow at a CAGR of 16.7% during the forecast period.
On the basis of biomolecules, the genetic biomarkers segment dominated the market in 2019 and is anticipated to maintain its dominance during the forecast period.
Comprehensive competitive analysis and profiles of major market cancer biomarkers market players such as Abbott Laboratories, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Exact Sciences Corporation, F.Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer, Inc., Qiagen N.V., Siemens AG, and Thermo Fisher Scientific, Inc. are provided in this report.
Companies Mentioned
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Company
- Exact Sciences Corporation
- F.Hoffmann-La Roche Ltd.
- Merck KGaA
- PerkinElmer, Inc.
- Qiagen N.V.
- Siemens AG
- Thermo Fisher Scientific, Inc.Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Company
- Exact Sciences Corporation
- F.Hoffmann-La Roche Ltd.
- Merck KGaA
- PerkinElmer, Inc.
- Qiagen N.V.
- Siemens AG
- Thermo Fisher Scientific, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 338 |
| Published | April 2020 |
| Forecast Period | 2019 - 2027 |
| Estimated Market Value ( USD | $ 10944.08 million |
| Forecasted Market Value ( USD | $ 26979.5 million |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
